BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Century Therapeutics Raises $160M for iPSC-derived CAR-T and CAR-NK Cell Therapeutics
Century Therapeutics iPSCs

Century Therapeutics Raises $160M for iPSC-derived CAR-T and CAR-NK Cell Therapeutics

April 1, 2021 By Cade Hildreth (CEO) Leave a Comment

In early March, Century Therapeutics made waves by raising $160 million in Series C financing. This was on top of the existing $250 million that the company raised during a Series A round in 2019, bringing its total financing to an astounding $410 million. The Series C financing round was led by Casdin Capital, a New York-based investment firm that targets life science and healthcare companies.

Discover class-defining bioproduction tools.

In total, twelve investors were involved, including several “heavy hitters” within the life science investment sector. These investors were: 

  1. Avidity Partners
  2. Casdin Capital
  3. Fidelity Management and Research Company LLC
  4. Federated Hermes Kaufmann Fund
  5. Leaps by Bayer
  6. Logos Capital
  7. Marshall Wace
  8. Octagon Capital Partners
  9. OrbiMed
  10. Qatar Investment Authority
  11. RA Capital Management
  12. Versant Ventures

Developing iPSC-Derived Cell Therapeutics

Headquartered in Philadelphia, PA, an hub for cell and gene therapy manufacturing innovation, Century Therapeutics has a unique market focus. The company specializes in creating genetically-engineered, universal induced pluripotent stem cell (iPSC) derived immuno-therapeutics to target hematologic and solid tumor cancers.

bitbio

Specifically, the company is developing iPSC-derived CAR-T and CAR-NK cell therapies, which it calls “CAR-iT” and “CAR-iNK” cell therapies. To create these cell therapeutics, Century Therapeutics utilizes a proprietary “allo-evasion” technology that enables its therapeutic candidates to avoid host rejection and promote cell persistence, allowing for a durable therapeutic response.

The company explains, “Century’s foundational technology is built on induced pluripotent stem cells (iPSCs) that have unlimited self-renewing capacity. This enables multiple rounds of cellular engineering to produce master cell banks of modified cells that can be expanded and differentiated into immune effector cells to supply vast amounts of allogeneic, homogeneous therapeutic products.”

Pluristyx

The company’s iPSC-derived CAR-expressing natural killer (NK) and T-cell therapeutics are on track to enter clinical trials for hematological and solid cancers in 2022.

Related: The Pipeline for iPSC-Derived Cell Therapeutics in 2021
To learn more about the burgeoning market for iPSCs, view the “Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2021.”
5/5 - (7 votes)

Filed Under: CAR-T, Cell Therapy, iPS Cells, Stem Cell News

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Cord Blood Market Segmentation

Cord Blood Market Segmentation – Biobanking, HSCT, Cellular Therapy, Genetic Manipulation, & Research Tools

CAR-T Companies

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.